(Q47984024)

http://europepmc.org/abstract/MED/28128970

7 February 2018

title

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. (English)

1 reference

http://europepmc.org/abstract/MED/28128970

7 February 2018

main subject

diagnosis

0 references

chronic obstructive pulmonary disease

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Peter J. Barnes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Nicolas Roche

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jørgen Vestbo

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

3

Fernando J Martinez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

7

Bartolome R Celli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

M Victorina López Varela

13

object named as

M Victorina López Varela

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Gerard J Criner

2

object named as

Gerard J Criner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jadwiga A Wedzicha

21

object named as

Jadwiga A Wedzicha

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Jean Bourbeau

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Rongchang Chen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Leonardo M Fabbri

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Peter Frith

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

David M G Halpin

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Masaharu Nishimura

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Roberto Rodriguez-Roisin

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Don D Sin

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Dave Singh

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Robert Stockley

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Alvar Agustí

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Antonio Anzueto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Marc Decramer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

27 January 2017

1 reference

http://europepmc.org/abstract/MED/28128970

7 February 2018

published in

American Journal of Respiratory and Critical Care Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

557-582

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Clinical and Radiologic Disease in Smokers With Normal Spirometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

COPD in never smokers: results from the population-based burden of obstructive lung disease study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Mild prematurity and respiratory functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Association of birth weight with adult lung function: findings from the British Women's Heart and Health Study and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effects of water-pipe smoking on lung function: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Marijuana and chronic obstructive lung disease: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Associations of Ambient Air Pollution with Chronic Obstructive Pulmonary Disease Hospitalization and Mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Indoor air pollution and health in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Lung function and incidence of chronic obstructive pulmonary disease after improved cooking fuels and kitchen ventilation: a 9-year prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Asthma as a risk factor for COPD in a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The relationship of nonspecific bronchial responsiveness to respiratory symptoms in a random population sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

HIV-associated obstructive lung diseases: insights and implications for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Tuberculosis, bronchiectasis and chronic airflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Tuberculosis and chronic respiratory disease: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Cachexia as a major underestimated and unmet medical need: facts and numbers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Does the clinical examination predict airflow limitation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

"GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study".

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Phenotype of normal spirometry in an aging population

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Phenotype of Spirometric Impairment in an Aging Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Counterpoint: Is an increase in FEV₁ and/or FVC ≥ 12% of control and ≥ 200 mL the best way to assess positive bronchodilator response? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Development of a simple screening tool for opportunistic COPD case finding in primary care in Latin America: The PUMA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Early detection of COPD in general practice: implementation, workload and socioeconomic status. A mixed methods observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Health status measurement in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A measure of quality of life for clinical trials in chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Characterisation of COPD heterogeneity in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

COPD and disease-specific health status in a working population

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Patterns of comorbidities in newly diagnosed COPD and asthma in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

GOLD 2011 disease severity classification in COPDGene: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Electronic Cigarettes for Smoking Cessation: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Association between electronic cigarette use and changes in quit attempts, success of quit attempts, use of smoking cessation pharmacotherapy, and use of stop smoking services in England: time series analysis of population trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Long-acting muscarinic antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Hospitalizations and mortality in the Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The safety of tiotropium--the FDA's conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Tiotropium Respimat inhaler and the risk of death in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Salmeterol plus theophylline combination therapy in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Value of theophylline treatment in patients handicapped by chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Inhaled corticosteroids and the risks of diabetes onset and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Use of inhaled and oral corticosteroids and the long-term risk of cataract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Withdrawal of inhaled corticosteroids in individuals with COPD--a systematic review and comment on trial methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Relapse in FEV1 Decline After Steroid Withdrawal in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Azithromycin for prevention of exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immuno

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Statin use and exacerbations in individuals with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Inhaler mishandling remains common in real life and is associated with reduced disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Levodropropizine in the management of cough associated with cancer or nonmalignant chronic disease--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Mortality of patients with COPD participating in chronic disease management programmes: a happy end?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of telehealth on quality of life and psychological outcomes over 12 months (Whole Systems Demonstrator telehealth questionnaire study): nested study of patient reported outcomes in a pragmatic, cluster randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Can early introduction of specialized palliative care limit intensive care, emergency and hospital admissions in patients with severe and very severe COPD? a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Surgical Approaches to Treating Emphysema: Lung Volume Reduction Surgery, Bullectomy, and Lung Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A randomised trial of lung sealant versus medical therapy for advanced emphysema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A randomized study of endobronchial valves for advanced emphysema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi trial): study design and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Pulmonary Rehabilitation Exercise Prescription in Chronic Obstructive Pulmonary Disease: Review of Selected Guidelines: AN OFFICIAL STATEMENT FROM THE AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY REHABILITATION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Aerobic and strength training in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A randomized trial to improve communication about end-of-life care among patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

COPD exacerbations: defining their cause and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Guidelines for the management of adult lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Pulmonary arterial enlargement and acute exacerbations of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Bronchodilator responsiveness in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

High-risk patients following hospitalisation for an acute exacerbation of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Lung function impairment, COPD hospitalisations and subsequent mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Noninvasive positive pressure ventilation to treat respiratory failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Predischarge bundle for patients with acute exacerbations of COPD to reduce readmissions and ED visits: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Association of Psychological Disorders With 30-Day Readmission Rates in Patients With COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The Association Between Hospital Readmission and Pulmonologist Follow-up Visits in Patients With COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Systemic manifestations and comorbidities of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Mortality in COPD: Role of comorbidities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Chronic obstructive pulmonary disease and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Beta-blockers in COPD: time for reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Cardiovascular events in patients with COPD: TORCH study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Influence of anxiety on health outcomes in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the pittsburgh lung screening study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Association of radiographic emphysema and airflow obstruction with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Reduced lung-cancer mortality with low-dose computed tomographic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Relationship of ventricular ectopy to nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Relationship Between Bacterial Flora in Sputum and Functional Impairment in Patients With Acute Exacerbations of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Short- and Medium-term Prognosis in Patients Hospitalized for COPD Exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

The prognostic importance of lung function in patients admitted with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

What community measurements can be used to predict bone disease in patients with COPD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Chinese water-pipe smoking and the risk of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Use of inhaled corticosteroids and the risk of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

Complex chronic comorbidities of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201701-0218PP

10.1164/RCCM.201701-0218PP

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28128970%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference